Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6Chi monocytes and differentiation to pro-angiogenic myeloid cells.
Tran T, Lavillegrand JR, Lereverend C, Esposito B, Cartier L, Montabord M, Tran-Rajau J, Diedisheim M, Gruel N, Ouguerram K, Paolini L, Lenoir O, Pinteaux E, Brabencova E, Tanchot C, Urquia P, Lehmann-Che J, Le Naour R, Merrouche Y, Stockmann C, Mallat Z, Tedgui A, Ait-Oufella H, Tartour E, Potteaux S. Tran T, et al. Among authors: brabencova e. Nat Commun. 2022 Sep 14;13(1):5399. doi: 10.1038/s41467-022-33034-0. Nat Commun. 2022. PMID: 36104342 Free PMC article.
Corrigendum: The NFAT3/RERG complex in luminal breast cancers is required to inhibit cell invasion and may be correlated with an absence of axillary lymph nodes colonization.
Coillard L, Guaddachi F, Ralu M, Brabencova E, Garbar C, Bensussan A, Le Bras M, Lehmann-Che J, Jauliac S. Coillard L, et al. Among authors: brabencova e. Front Oncol. 2022 Aug 30;12:1016189. doi: 10.3389/fonc.2022.1016189. eCollection 2022. Front Oncol. 2022. PMID: 36110951 Free PMC article.
The human epidermal growth factor receptor 2 screening tests for breast cancer suggested by the new updated recommendation of the american society of clinical oncology/college of american pathologists will involve a rise of the in-situ hybridization tests for the European laboratories of pathology.
Garbar C, Savoye AM, Mascaux C, Brabencova E, Curé H. Garbar C, et al. Among authors: brabencova e. ISRN Oncol. 2014 Apr 22;2014:793695. doi: 10.1155/2014/793695. eCollection 2014. ISRN Oncol. 2014. PMID: 24944830 Free PMC article.
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Poulet B, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS. Penault-Llorca F, et al. Among authors: brabencova e. Ann Pathol. 2014 Oct;34(5):352-65. doi: 10.1016/j.annpat.2014.08.018. Epub 2014 Sep 26. Ann Pathol. 2014. PMID: 25439988 French.
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].
Maran-Gonzalez A, Franchet C, Duprez-Paumier R, Antoine M, Barlier C, Becette V, Berghian A, Blanc-Fournier C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Fleury C, Garbar C, Ghnassia JP, Haudebourg J, MacGrogan G, Mathieu MC, Michenet P, Penault-Llorca F, Poulet B, Robin Y, Roger P, Russ E, Treilleux I, Valent A, Verriele V, Vincent-Salomon A, Arnould L, Lacroix-Triki M; GEFPICS. Maran-Gonzalez A, et al. Among authors: brabencova e. Ann Pathol. 2019 Dec;39(6):383-398. doi: 10.1016/j.annpat.2019.04.004. Epub 2019 Jun 27. Ann Pathol. 2019. PMID: 31257035 Review. French.
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].
MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, Treilleux I, Valent A, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS. MacGrogan G, et al. Among authors: brabencova e. Ann Pathol. 2014 Oct;34(5):366-72. doi: 10.1016/j.annpat.2014.08.017. Epub 2014 Sep 26. Ann Pathol. 2014. PMID: 25439989 French.
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
Penault-Llorca F, Vincent-Salomon A, Bellocq JP, Matthieu MC, Grogan GM, Treilleux I, Ettore F, Laberge-Le Couteulx S, Sigal B, Couturier J, Lacroix-Triki M, Antoine M, Balaton A, Baranzelli MC, Becette V, Blanc-Fournier C, Bibeau F, Brabencova E, Croce S, Fridman V, Génin P, Ghnassia JP, Jacquemier J, Poulet B, Roger P, Sagan C, Tas P, Trassard M, Verriele V, Arnould L; GEFPICS. Penault-Llorca F, et al. Among authors: brabencova e. Ann Pathol. 2010 Oct;30(5):357-73. doi: 10.1016/j.annpat.2010.07.001. Epub 2010 Oct 16. Ann Pathol. 2010. PMID: 21055523 French.
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France].
Franchet C, Djerroudi L, Maran-Gonzalez A, Abramovici O, Antoine M, Becette V, Berghian A, Blanc-Fournier C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Duprez-Paumier R, Fleury C, Ghnassia JP, Haudebourg J, Leroux A, MacGrogan G, Mathieu MC, Michenet P, Penault-Llorca F, Poulet B, Robin YM, Roger P, Russ E, Tixier L, Treilleux I, Valent A, Verriele V, Vincent-Salomon A, Arnould L, Lacroix-Triki M; Pour le GEFPICS. Franchet C, et al. Among authors: brabencova e. Ann Pathol. 2021 Nov;41(6):507-520. doi: 10.1016/j.annpat.2021.07.014. Epub 2021 Aug 12. Ann Pathol. 2021. PMID: 34393014 French.
24 results